Date of improved response rates in mantle cell lymphoma patients

MD Anderson Cancer Center shared on LinkedIn:

“Adding the BTK inhibitor acalabrutinib to chemoimmunotherapy shows improved response rates in mantle cell lymphoma patients, according to primary data presented by our Dr Michael Wang at the 2024 European Hematology Association Annual General Meeting.

See more research presented by our experts at EHA2024.”

Source: MD Anderson Cancer Center/LinkedIn